换一批
换一批A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial.
作者：
主题词
科学院和研究所(Academies and Institutes);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);加拿大(Canada);女(雌)性(Female);造血干细胞移植(Hematopoietic Stem Cell Transplantation);人类(Humans);男(雄)性(Male);医学肿瘤学(Medical Oncology);中年人(Middle Aged);多发性骨髓瘤(Multiple Myeloma);泼尼松(Prednisone);生活质量(Quality of Life);存活率分析(Survival Analysis);沙立度胺(Thalidomide);移植, 自体(Transplantation, Autologous);治疗结果(Treatment Outcome)
DOI
10.1182/blood-2012-09-451872
PMID
23297129
发布时间
2021-10-21
- 浏览21
Blood
1517-23页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
